Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14576 - 14600 of 15222 in total
Deudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis).
Investigational
Matched Description: … Deudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and
Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).
Investigational
Matched Description: … in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
Matched Description: … is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and
Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).
Investigational
Matched Description: … Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 …
Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).
Investigational
Matched Description: … Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 …
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Matched Description: … U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Investigational
Matched Description: … Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory …
Befotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive Patients With Advanced Egfr-mutant Lung Cancer).
Investigational
Matched Description: … Befotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive …
Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection).
Investigational
Matched Description: … Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol …
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and
Displaying drugs 14576 - 14600 of 15222 in total